TruVision Single-Use 1.9mm Arthroscopy System
Nexus CMF, LLC · Decision date Oct 9, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision on 2026-10-09 for K260156, the TruVision Single-Use 1.9mm Arthroscopy System, submitted by Nexus CMF, LLC of Salt Lake City, Utah. The record lists the device classification as Arthroscope under regulation 888.1100, product code HRX, with an Orthopedic medical specialty and review panel. The application was received 01/20/2026 as a Traditional 510(k); the record states it was not reviewed by a third party, is not a combination product, and has no authorized Predetermined Change Control Plan.
SESE in a 510(k) means the device was cleared as substantially equivalent to a legally marketed predicate; it is not a PMA approval. The public record does not identify the predicate device, summarize the comparative data, or describe indications, components or use instructions, so those details remain unknown from this source. The same decision appears in the FDA final-decisions listing dated 09 Oct 2026.
No clinical or legal conclusion about the device's performance or labeling is supported by the available fields.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Orthopedic
- Decision date
- Oct 9, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K260156
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Nexus CMF, LLC
- Product code
- HRX
- Decision code
- SESE
- Decision date
- Oct 9, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Arthroscope.
- Applicant
- Nexus CMF, LLC
- Product code
- HRX
- FDA device class
- 2
FDA decision timeline
K260156 received
Application receipt date recorded by FDA.
K260156 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code HRX
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| SurGenTec, LLC | 510(k) clearance | Oct 14, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Nexus CMF, LLC
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Salt Lake City, UT
Sources and methodology
- Original FDA record: K260156
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records